Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutra Pharma Plans To Launch Nyloxin Rx
Nutra Pharma has revealed plans to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain. Nyloxin Rx is a prescription pain reliever
Nutra Pharma has revealed plans to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain. Nyloxin Rx is a prescription pain reliever
3M Drug Delivery Systems has reported the expansion of its capabilities with a new laboratory site at the 3M Singapore facility in Yishun. Reportedly, the Singapore lab will
The Chinese Military Drug Administration has granted clearance to Biostar Pharmaceuticals to begin clinical trials on its new drug application, the Zushima Analgesic Aerosol Spray. The company said
Impax Laboratories has reached an agreement with Astellas Pharma and Boehringer Ingelheim to settle pending US litigation with regard to US Patent for Flomax capsules, through the entry
Mannatech has secured a second injunction in its ongoing efforts to protect its glyconutrient products – Ambrotose complex and Advanced Ambrotose formula. The company said that the US
Nova Biomedical has revealed that its independent, wholly-owned subsidiary, Sanvita CBGM, has completed the acquisition of certain assets of Sanvita, a subsidiary of CCS Medical. The company said
Quest Diagnostics has revealed that it is performing DNA testing for gene variants that can increase the risk of major coronary events in certain patients taking the anti-clotting
Synexus has reportedted that it has already run several large late phase clinical trials for cancer vaccines and has a tried and tested recruitment methodology, which rapidly finds
Sandoz has launched its recombinant human growth hormone somatropin in Japan. The launch follows the precedent-setting approval of somatropin – marketed as Omnitrope in the EU, the US,
Orexo said that its partner ProStrakan has reported that the New Drug Application (NDA) filing for Abstral has been accepted for review by the FDA. Abstral is a